PARS2
Overview
PARS2 encodes prolyl-tRNA synthetase 2, a mitochondrial aminoacyl-tRNA synthetase. It is notable in cancer genomics as a fusion partner generating PARS2-NOTCH2 rearrangements, which represent a functionally distinct class of NOTCH fusions predicted to be insensitive to gamma-secretase inhibitors.
Alterations observed in the corpus
- PARS2-NOTCH2 fusion identified in the MET500 pan-cancer metastatic cohort (n=500); this fusion class is predicted to be gamma-secretase-inhibitor-independent (contrast with NOTCH2-SPAG17 fusions which are gamma-secretase-sensitive), guiding differential therapy selection among NOTCH-fusion-positive tumors PMID:28783718
Cancer types (linked)
Co-occurrence and mutual exclusivity
Therapeutic relevance
- PARS2-NOTCH2 fusions are predicted gamma-secretase-inhibitor-insensitive, in contrast to NOTCH2-SPAG17 class fusions; subclassification of NOTCH fusions is necessary before selecting gamma-secretase inhibitor therapy PMID:28783718
Open questions
- The specific cancer type(s) in which PARS2-NOTCH2 fusions arise within the MET500 cohort are not specified; functional validation of the predicted gamma-secretase insensitivity is pending.
Sources
This page was processed by entity-page-writer on 2026-05-15.